HONG KONG, Dec. 7, 2017 /PRNewswire/ -- China Cord Blood
Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services, today announced the results of its
2017 Annual General Meeting, which was held on December 7, 2017, in Hong Kong S.A.R.,
China.
At the Annual General Meeting, shareholders
- ratified the re-appointment of KPMG Huazhen LLP as auditors of
the Company for the financial year ending March 31, 2018 and authorized any duly formed committee of the
directors to fix the remuneration of the auditors; and
- re-elected Ms. Ting Zheng and Dr. Ken
Lu as Class B directors of the Company until the 2020 annual
general meeting of the Company or until their respective successors
are duly appointed and qualified.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses. Under
current PRC government regulations, only one licensed cord blood
banking operator is permitted to operate in each licensed region
and no new licenses will be granted before 2020 in addition to the
seven licenses authorized as of today. China Cord Blood Corporation
provides cord blood collection, laboratory testing, hematopoietic
stem cell processing and stem cell storage services. For more
information, please visit the Company's website at
http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511 (China) or
(+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/china-cord-blood-corporation-announces-results-of-2017-annual-general-meeting-300568199.html
SOURCE China Cord Blood Corporation